ArticleJournal of neurology, neurosurgery, and psychiatry2021
Neuroinflammation predicts disease progression in progressive supranuclear palsy.
Article in Journal of neurology, neurosurgery, and psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Pooled it
- Disease-specific tau polymorphs are associated with unique protein networks across proteinopathies.The EMBO journal · 2026Article
- Associations Between Nonspecific Blood-Derived Inflammatory Indices and MRI-Derived Frontal Network Degeneration in Progressive Supranuclear Palsy.Neurology international · 2026Article
- Natural Killer Subset Changes and Vascular Endothelial Growth Factor-A Plasma Profile in Progressive Supranuclear Palsy: The NKscape Study.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Regional mapping of CSF1R-positive microglia in neurodegenerative diseases and progressive MS, with exploratory presynaptic marker analyses.Journal of neuroinflammation · 2026Article
- Distinct plasma inflammatory signatures reflect disease severity and progression in progressive supranuclear palsy: a prospective cohort study.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Subtracting First Principal Component May Improve 4R Tau Detectability on [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Comparing and combining TSPO-PET tracers in tauopathies.European journal of nuclear medicine and molecular imaging · 2026Article
- From clinical phenotypes to molecular precision: multimodal biomarkers for progressive supranuclear palsy.Frontiers in neuroscience · 2026Review
- 4R-tau seeding activity reveals molecular subtypes in progressive supranuclear palsy.Nature communications · 2025Article
- Inflammatory and Neurotrophic Factors and Their Connection to Quality of Life in Progressive Supranuclear Palsy-Single-Center Study.International journal of molecular sciences · 2025Article
- Diagnostic utility of biomarkers in progressive supranuclear palsy: toward a biotyping framework.Journal of neurology · 2025Review
- Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Distinct 11C-ER176 PET Neuroinflammatory Profiles and Tau Colocalization in Progressive Apraxia of Speech With and Without Parkinson-plus Syndrome.Clinical nuclear medicine · 2025Article
- Midbrain cytotoxic T cells as a distinct neuropathological feature of progressive supranuclear palsy.Brain : a journal of neurology · 2025Article
- Multifactorial etiology of progressive supranuclear palsy (PSP): the genetic component.Acta neuropathologica · 2025Review
- Post-mortem validation of in vivo TSPO PET as a microglial biomarker.Brain : a journal of neurology · 2025Article
- Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Pathomechanisms of neuropsychiatric disturbances in atypical parkinsonian disorders: a current view.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
introductionIn addition to tau pathology and neuronal loss, neuroinflammation occurs in progressive supranuclear palsy (PSP). However, the prognostic value of the in vivo imaging markers for these processes in PSP remains unclear. We test the primary hypothesis that baseline in vivo imaging assessment of neuroinflammation in subcortical regions predicts clinical progression in patients with PSP.
methodsSeventeen patients with PSP-Richardson's syndrome underwent a baseline multimodal imaging assessment, including [
resultsPCA components reflecting neuroinflammation and tau burden in the brainstem and cerebellum correlated with the subsequent annual rate of change in the PSPRS. PCA-derived PET markers of neuroinflammation and tau pathology correlated with regional brain volume in the same regions. However, MRI volumes alone did not predict the rate of clinical progression.
conclusionsMolecular imaging with PET for microglial activation and tau pathology can predict clinical progression in PSP. These data encourage the evaluation of immunomodulatory approaches to disease-modifying therapies in PSP and the potential for PET to stratify patients in early phase clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.